Ultimovacs ASA (ULTI.OL)

NOK 2.76

(14.79%)

Market Cap (In NOK)

94.76 Million

Revenue (In NOK)

-

Net Income (In NOK)

-189.23 Million

Avg. Volume

414.21 Thousand

Currency
NOK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.57-165.0
PE
-
EPS
-
Beta Value
0.986
ISIN
NO0010851603
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Carlos de Sousa
Employee Count
-
Website
https://ultimovacs.com
Ipo Date
2019-06-03
Details
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.